FDA Approves UCB's Keppra® for Use in Childhood Epilepsy
24 juin 2005 01h00 HE
|
UCB
Brussels (Belgium), June 24, 2005 - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved the company's anti-epilepsy drug Keppra® (levetiracetam) as add-on therapy in the...
UCB Confirms Positive Financial Outlook for 2005
14 juin 2005 01h00 HE
|
UCB
Brussels, June 14, 2005 - At today's Annual General Shareholders' Meeting, Roch Doliveux, CEO of UCB, made the following statement:
"Innovation and globalisation: the foundation on...
UCB and Lonza Enter Into a Strategic Bio-Manufacturing Alliance
13 mai 2005 01h00 HE
|
UCB
Brussels and Basel, 13 May 2005 - UCB and Lonza have signed a long-term supply agreement, under which Lonza will manufacture PEGylated antibody fragment based bulk actives for UCB. Lonza is building a...
UCB Confirms Strong Quarterly Sales In The Us Xyzal Sells More Than Zyrtec In Europe
19 avr. 2005 01h00 HE
|
UCB
Brussels, 19 April 2005 - Following Pfizer's first quarter 2005 earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine...
Of Co-Distributor For Zyrtec® In Japan
18 avr. 2005 01h15 HE
|
UCB
Tokyo (Japan) - April 18, 2005 - UCB Japan Co., Ltd. (UCB Japan) and GlaxoSmithKline K.K. (GSK Japan) announced that GSK Japan will be the new codistributor for Zyrtec® tablet 5mg and Zyrtec® tablet...
UCB Announces European Launch Of Kentera(TM) The First European Transdermal Oxybutynin Treatment For Overactive Bladder
18 avr. 2005 01h00 HE
|
UCB
Brussels, April 18, 2005 - UCB, a leading global biopharmaceutical company, today confirmed that its novel oxybutynin transdermal patch for overactive bladder (OAB) is to begin its phased European...
First evidence of efficacy for UCB's Keppra®* in the adjunctive treatment of myoclonic seizures
31 mars 2005 00h00 HE
|
UCB
Brussels, BELGIUM, 31 March 2005) - UCB today announced the first evidence from a major study showing that Keppra® (levetiracetam) is effective for adjunctive treatment of myoclonic seizures in...
UCB Group confirms its previously announced 2004 results and provides IFRS reconciliation and product update
23 mars 2005 01h00 HE
|
UCB
Financial Highlights
UCB Group confirms net income after tax increased by 7% to € 363 million (19% at constant exchange rates) under Belgian GAAP.
Dividend increases by 5%.
IFRS conversion...
UCB: Closing Of The Sale Of Its Surface Specialties Division
01 mars 2005 01h00 HE
|
UCB
Brussels - March 1st, 2005 - UCB confirms today the closing of sale of its Surface Specialties business to Cytec Industries Inc. a global technology leader in specialty chemicals and specialty...
FDA grants priority review to levetiracetam for use in childhood epilepsy
17 févr. 2005 01h00 HE
|
UCB
Brussels, 17 February 2005: UCB Pharma Inc has been granted a priority review for the supplemental new drug application (sNDA) seeking approval of its leading anti-epilepsy drug (AED) Keppra®*...